CAMP4 Therapeutics Corporation reported its financial results for the first quarter ended March 31, 2025, along with corporate highlights. The company's cash, cash equivalents, and marketable securities totaled $49.3 million as of March 31, 2025, a decrease from $64.0 million at December 31, 2024.
Research and development expenses for the quarter increased to $10.1 million from $9.7 million in Q1 2024, primarily due to increased clinical and preclinical study costs. General and administrative expenses also rose to $3.8 million from $3.1 million in the prior-year quarter. The net loss for the quarter was $12.4 million, comparable to $12.5 million in Q1 2024.
Operationally, CAMP4 submitted a Clinical Trial Application (CTA) in Europe for a Phase 1b expansion study of CMP-CPS-001 in female OTC heterozygotes, pending regulatory clearance. The company remains on track to release safety, pharmacokinetic, and pharmacodynamic data from the Multiple Ascending Dose (MAD) portion of this Phase 1 study in Q4 2025. Furthermore, CAMP4 became eligible to receive a milestone payment from Fulcrum Therapeutics under a license agreement signed in July 2023 for its DBA program. Preclinical data for CMP-SYNGAP-01 showed a meaningful increase in SYNGAP1 protein levels in non-human primates following intrathecal administration, demonstrating strong translational potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.